What is HC Wainwright's Estimate for Omeros FY2026 Earnings?

Omeros logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate for Omeros to a loss of $0.08 per share from a projected loss of $0.37, while reiterating its Buy rating and $33 price target.
  • The firm also forecasts EPS of $1.56 in FY2028, $3.77 in FY2029 and $4.91 in FY2030. Analysts’ consensus rating is Moderate Buy, with an average price target of $30.33.
  • Omeros reported quarterly EPS of $0.06, beating the $0.02 consensus estimate, but revenue of $35.93 million fell short of the $37.28 million forecast.
  • MarketBeat previews the top five stocks to own by December 1st.

Omeros Corporation (NASDAQ:OMER - Free Report) - Stock analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Omeros in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings per share of ($0.08) for the year, up from their prior estimate of ($0.37). HC Wainwright has a "Buy" rating and a $33.00 price target on the stock. The consensus estimate for Omeros' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for Omeros' Q4 2026 earnings at ($0.08) EPS, FY2028 earnings at $1.56 EPS, FY2029 earnings at $3.77 EPS and FY2030 earnings at $4.91 EPS.

A number of other equities analysts also recently weighed in on OMER. Cantor Fitzgerald reissued an "overweight" rating and issued a $22.00 price target on shares of Omeros in a report on Wednesday, October 14th. Wall Street Zen upgraded shares of Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Omeros has a consensus rating of "Moderate Buy" and an average target price of $30.33.

View Our Latest Stock Analysis on OMER

Omeros Price Performance

Shares of Omeros stock opened at $14.55 on Thursday. The firm has a market cap of $1.05 billion, a PE ratio of 15.16 and a beta of 2.96. Omeros has a 1 year low of $6.70 and a 1 year high of $21.24. The stock has a fifty day moving average price of $18.02 and a 200-day moving average price of $13.79.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The business had revenue of $35.93 million during the quarter, compared to the consensus estimate of $37.28 million.

Insider Activity at Omeros

In other Omeros news, CAO David J. Borges sold 10,000 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total transaction of $209,500.00. Following the completion of the transaction, the chief accounting officer directly owned 5,000 shares of the company's stock, valued at approximately $104,750. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Peter B. Cancelmo sold 25,000 shares of the firm's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the sale, the vice president directly owned 200 shares of the company's stock, valued at $3,708. This represents a 99.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 85,906 shares of company stock worth $1,628,205. Insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Omeros by 3.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,708 shares of the biopharmaceutical company's stock worth $302,000 after acquiring an additional 589 shares during the period. Sterling Capital Management LLC increased its holdings in Omeros by 75.3% in the 3rd quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 758 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Omeros by 13.6% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,500 shares of the biopharmaceutical company's stock worth $333,000 after acquiring an additional 2,100 shares during the last quarter. Brighton Jones LLC raised its stake in Omeros by 9.9% in the 3rd quarter. Brighton Jones LLC now owns 34,739 shares of the biopharmaceutical company's stock valued at $661,000 after acquiring an additional 3,142 shares during the period. Finally, GK Wealth Management LLC bought a new stake in Omeros in the 3rd quarter valued at about $65,000. Hedge funds and other institutional investors own 48.79% of the company's stock.

Latest Omeros News

Investors following OMER have been watching these news items:

  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $33 price target, raising its FY2026 EPS estimate to a loss of $0.08 from a loss of $0.37, and lifting its FY2027, FY2029 and FY2030 forecasts. The improved longer-term outlook could support sentiment. Omeros earns Buy rating from HC Wainwright
  • Neutral Sentiment: HC Wainwright trimmed its FY2028 EPS estimate to $1.56 from $1.63, a modest counterpoint to its raised forecasts for other years. HC Wainwright stock recommendations
  • Negative Sentiment: Q3 results disappointed on revenue, and reports cited a European setback for Yartemlea. Those concerns appear to have outweighed sales growth and helped drive sharp recent pressure on the shares. Omer stock eyes worst day with European Yartemlea setback

Omeros Company Profile

(Get Free Report)

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Featured Articles

Earnings History and Estimates for Omeros (NASDAQ:OMER)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omeros Right Now?

Before you consider Omeros, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.

While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines